Home > Oncology > ASCO 2022 > Miscellaneous Topics > New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

Presented By
Prof. Vanita Noronha, Tata Memorial Hospital, India
Conference
ASCO 2022
Doi
https://doi.org/10.55788/ff6e6173
Docetaxel added to radiation improved the disease-free survival (DFS) and overall survival (OS) of patients with locally advanced head-and-neck squamous cell carcinoma (LAHNSCC). The current randomised trial is the first study to assess docetaxel as a radiosensitiser in cisplatin-ineligible patients with LAHNSCC and resulted in the presentation of a new reference standard-of-care for this population.  Although chemoradiation with cisplatin is a main standard therapy for patients with LAHNSCC, patients who are unsuitable to receive cisplatin are not uncommon. Prof. Vanita Noronha (Tata Memorial Hospital, India) discussed a phase 3 trial that randomised patients with LAHNSCC, who were ineligible for cisplatin, to radiotherapy alone (n=176) or docetaxel and radiotherapy (n=180) [1]. The main outcomes of the trial were DFS and OS after 2 years, quality-of-life, and adverse events (AEs). The 2-year DFS was significantly higher ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on